Total Payments
$951,661
2024 Payments
$156,719
Companies
30
Transactions
862
Medicare Patients
5,890
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$728,935 (76.6%)
Travel$94,927 (10.0%)
Consulting$93,155 (9.8%)
Food & Beverage$32,846 (3.5%)
Research$1,516 (0.2%)
Education$281.82 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $691,561 | 177 | 72.7% |
| Travel and Lodging | $94,927 | 169 | 10.0% |
| Consulting Fee | $93,155 | 38 | 9.8% |
| Food and Beverage | $32,846 | 435 | 3.5% |
| Honoraria | $25,888 | 14 | 2.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $11,313 | 12 | 1.2% |
| Unspecified | $1,516 | 7 | 0.2% |
| Education | $281.82 | 7 | 0.0% |
| Entertainment | $174.70 | 3 | 0.0% |
Payments by Type
General
$950,145
855 transactions
Research
$1,516
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | $253,045 | 114 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $241,302 | 156 | $0 (2024) |
| ABBVIE INC. | $147,867 | 139 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $104,866 | 65 | $0 (2019) |
| Allergan, Inc. | $63,130 | 88 | $0 (2022) |
| Bausch & Lomb Americas Inc. | $27,852 | 42 | $0 (2024) |
| Amgen Inc. | $27,497 | 41 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $21,704 | 29 | $0 (2021) |
| Horizon Therapeutics plc | $16,628 | 29 | $0 (2023) |
| Alimera Sciences, Inc. | $13,398 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156,719 | 125 | Mallinckrodt Hospital Products Inc. ($84,070) |
| 2023 | $138,924 | 111 | Mallinckrodt Hospital Products Inc. ($54,284) |
| 2022 | $86,320 | 89 | Regeneron Healthcare Solutions, Inc. ($32,814) |
| 2021 | $92,348 | 80 | Mallinckrodt Hospital Products Inc. ($48,241) |
| 2020 | $90,323 | 55 | Mallinckrodt Hospital Products Inc. ($43,330) |
| 2019 | $243,827 | 184 | Regeneron Healthcare Solutions, Inc. ($110,012) |
| 2018 | $86,450 | 120 | AbbVie, Inc. ($43,611) |
| 2017 | $56,749 | 98 | AbbVie, Inc. ($40,395) |
All Payment Transactions
862 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Genentech, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/13/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $637.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,180.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| 12/05/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $15.80 | General |
| 11/26/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,490.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $10.14 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $98.92 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/14/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $85.46 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/13/2024 | Genentech, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $141.18 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/13/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $70.90 | General |
| Category: Ophthalmology | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/12/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $896.95 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $674.18 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $125.35 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $92.64 | General |
| Category: IMMUNOLOGY | ||||||
| 10/18/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $147.98 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $1,455 | 6 |
| A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non infectious Uveitis | Gilead Sciences, Inc. | $61.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,353 | 7,356 | $1.1M | $328,330 |
| 2022 | 9 | 1,469 | 2,932 | $1.3M | $328,407 |
| 2021 | 13 | 1,650 | 3,609 | $1.8M | $445,110 |
| 2020 | 11 | 1,418 | 2,994 | $1.3M | $324,058 |
Total Patients
5,890
Total Services
16,891
Medicare Billing
$1.4M
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 20 | 4,800 | $219,480 | $106,550 | 48.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 24 | 154 | $394,050 | $98,199 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 170 | 358 | $76,970 | $23,393 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 118 | 206 | $59,946 | $17,776 | 29.7% |
| 92134 | Imaging of retina | Office | 2023 | 271 | 478 | $66,920 | $13,275 | 19.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 53 | 155 | $78,960 | $12,749 | 16.1% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2023 | 12 | 13 | $60,099 | $12,277 | 20.4% |
| 92134 | Imaging of retina | Facility | 2023 | 302 | 653 | $58,770 | $11,107 | 18.9% |
| 67028 | Injection of drug into eye | Facility | 2023 | 54 | 163 | $59,675 | $10,720 | 18.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 135 | 156 | $31,356 | $9,259 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 125 | 151 | $21,140 | $7,258 | 34.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 30 | 30 | $10,530 | $2,838 | 26.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $9,261 | $2,419 | 26.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2023 | 18 | 18 | $2,736 | $511.20 | 18.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 40 | 278 | $727,050 | $186,615 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 155 | 328 | $70,520 | $22,338 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 207 | $60,237 | $17,618 | 29.2% |
| 92134 | Imaging of retina | Office | 2022 | 286 | 553 | $77,420 | $15,937 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 169 | 214 | $43,014 | $13,522 | 31.4% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2022 | 11 | 13 | $60,099 | $13,107 | 21.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 48 | 146 | $72,480 | $12,620 | 17.4% |
| 92134 | Imaging of retina | Facility | 2022 | 339 | 707 | $63,630 | $12,302 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 184 | 250 | $35,000 | $11,436 | 32.7% |
| 67028 | Injection of drug into eye | Facility | 2022 | 49 | 145 | $54,049 | $10,579 | 19.6% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2022 | 12 | 12 | $37,236 | $6,652 | 17.9% |
About Dr. Rajiv Shah, MD
Dr. Rajiv Shah, MD is a Ophthalmology healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1396986329.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajiv Shah, MD has received a total of $951,661 in payments from pharmaceutical and medical device companies, with $156,719 received in 2024. These payments were reported across 862 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($691,561).
As a Medicare-enrolled provider, Shah has provided services to 5,890 Medicare beneficiaries, totaling 16,891 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Winston Salem, NC
- Active Since 03/22/2009
- Last Updated 08/31/2016
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1396986329
Products in Payments
- ACTHAR (Biological) $357,911
- EYLEA (Biological) $207,312
- Humira (Biological) $121,251
- OZURDEX (Drug) $87,219
- EYLEA HD (Biological) $38,199
- XIPERE (Drug) $31,517
- TEPEZZA (Biological) $26,860
- TEPEZZA (Drug) $16,628
- RETISERT (Drug) $16,066
- ILUVIEN (Drug) $11,442
- YUTIQ (Drug) $5,519
- Vabysmo (Drug) $4,299
- Lucentis (Biological) $3,291
- BEOVU (Drug) $2,322
- EYLEA AFLIBERCEPT INJECTION (Biological) $2,045
- Non-Covered Product (Drug) $1,368
- VYZULTA (Drug) $1,241
- DAILIES (Device) $422.77
- Susvimo (Drug) $383.22
- Constellation (Device) $353.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Winston Salem
Keith Walter, Md, MD
Ophthalmology — Payments: $722,167
Ophthalmology $722,167
Dr. Vishak John, M.d, M.D
Ophthalmology — Payments: $202,813
Ophthalmology $202,813
Charles Richards, Md, MD
Ophthalmology — Payments: $9,728
Ophthalmology $9,728
Margaret Greven, M.d, M.D
Ophthalmology — Payments: $7,794
Ophthalmology $7,794
Dr. Vickas Khemsara, Md, MD
Ophthalmology — Payments: $6,351
Ophthalmology $6,351
Akshay Mentreddy, Do, DO
Ophthalmology — Payments: $4,975
Ophthalmology $4,975